A Multicenter Study of Antifungal Use and Species Distribution and Antifungal Susceptibilities of Candida Isolates in South Korea
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background: Candidiasis control should include monitoring the epidemiology and resistance to various antifungal agents. In this study, the researchers investigated the Candida species recovered from clinical specimens at particular geographic areas or hospitals. Objective: The present study is geared toward the evaluation of antifungal drug usage at Korean hospitals in 2016. It is also essential that species distribution and antifungal susceptibilities of Candida isolates should be looked into to provide important data that can help devise therapeutic strategies to control the disease. Methods: Systemic antifungal agent usage over a one-year period was investigated at 10 Korean hospitals. Identification and antifungal susceptibility tests were performed on clinical isolates of the Candida species, which were collected over a three-month period. Results: The total antifungal usage in each hospital ranged from 7.7 to 158.9 defined daily doses (DDDs) per 1,000 patient days. Fluconazole was most commonly used (37.1%), followed by amphotericin B (30.6%), itraconazole (9.7%), echinocandins (8.8%), voriconazole (7.5%), and posaconazole (6.3%), respectively. Among 274 Candida isolates, C. albicans was the most frequently recovered (51.1%), followed by C. glabrata (15.7%), C. tropicalis (15.0%), and C. parapsilosis (13.5%), respectively. Through the application of either species-specific clinical breakpoints or epidemiological cutoff values to Candida isolates, the non-susceptibility rates to fluconazole, voriconazole, amphotericin B, and micafungin were found in 20.7%, 5.6%, 0%, and 0% of isolates, respectively. Conclusion: This nationwide multicenter study showed that total antifungal use varied considerably according to each hospital. Non-susceptibility to fluconazole should be further monitored, considering the drug's frequent use in Korea.
Abstract
Background: Candidiasis control should include monitoring the epidemiology and resistance to various antifungal agents. In this study, the researchers investigated the Candida species recovered from clinical specimens at particular geographic areas or hospitals. Objective: The present study is geared toward the evaluation of antifungal drug usage at Korean hospitals in 2016. It is also essential that species distribution and antifungal susceptibilities of Candida isolates should be looked into to provide important data that can help devise therapeutic strategies to control the disease. Methods: Systemic antifungal agent usage over a one-year period was investigated at 10 Korean hospitals. Identification and antifungal susceptibility tests were performed on clinical isolates of the Candida species, which were collected over a three-month period. Results: The total antifungal usage in each hospital ranged from 7.7 to 158.9 defined daily doses (DDDs) per 1,000 patient days. Fluconazole was most commonly used (37.1%), followed by amphotericin B (30.6%), itraconazole (9.7%), echinocandins (8.8%), voriconazole (7.5%), and posaconazole (6.3%), respectively. Among 274 Candida isolates, C. albicans was the most frequently recovered (51.1%), followed by C. glabrata (15.7%), C. tropicalis (15.0%), and C. parapsilosis (13.5%), respectively. Through the application of either species-specific clinical breakpoints or epidemiological cutoff values to Candida isolates, the non-susceptibility rates to fluconazole, voriconazole, amphotericin B, and micafungin were found in 20.7%, 5.6%, 0%, and 0% of isolates, respectively. Conclusion: This nationwide multicenter study showed that total antifungal use varied considerably according to each hospital. Non-susceptibility to fluconazole should be further monitored, considering the drug's frequent use in Korea.
참고문헌 (15)
- Pfaller MA, "Epidemiology of invasive candidiasis : a persistent public health problem", Clin Microbiol Rev, 20, pp.133~163 (2007)
- Pappas PG, "Clinical practice guideline for the management of candidiasis : 2016 update by the Infectious Diseases Society of America", Clin Infect Dis, 62, pp.e1~50 (2016)
- Kim SH, "The relationship between antifungal usage and antifungal susceptibility in clinical isolates of Candida : a multicenter Korean study", Med Mycol, 47, pp.296~304 (2009)
- Fournier P, "Antifungal use influences Candida species distribution and susceptibility in the intensive care unit", J Antimicrob Chemother, 66, pp.2880~2886 (2011)
- Won EJ, "Antifungal susceptibilities of bloodstream isolates of Candida species from nine hospitals in Korea : application of new antifungal breakpoints and relationship to antifungal usage", PLoS One, 10, pp.e0118770~ (2015)
- 원은정, "2011년 국내 12개 병원에서 분리된 효모균과 균사형 진균의 분포", Annals of Clinical Microbiology, 16(2), pp.92~100 (2013), 대한임상미생물학회[DOI]
- Merlo J, "Comparison of dose standard units for drug utilisation studies", Eur J Clin Pharmacol, 50, pp.27~30 (1996)
- Tae-Hyoung Kim, "Identification of Uncommon Candida Species Using Commercial Identification Systems", Journal of Microbiology and Biotechnology, 26(12), pp.2206~2213 (2016), 한국미생물·생명공학회[DOI]
- Clinical and Laboratory Standards Institute, "Performance standards for antifungal susceptibility testing of yeasts" (2017), Clinical and Laboratory Standards Institute
- Clinical and Laboratory Standards Institute, "Reference method for broth dilution antifungal susceptibility testing of yeasts" (2012), Clinical and Laboratory Standards Institute
- Pfaller MA, "Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010to 2012", J Clin Microbiol, 50, pp.2846~2856 (2012)
- Pfaller MA, "Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011 : application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance", J Clin Microbiol, 51, pp.2571~2581 (2013)
- Tan TY, "Antifungal susceptibility of invasive Candida bloodstream isolates from the Asia-Pacific region", Med Mycol, 54, pp.471~477 (2016)
- Lee WG, "First three reported cases of nosocomial fungemia caused by Candida auris", J Clin Microbiol, 49, pp.3139~3142 (2011)
- 박민승, "First Case of Echinocandin-Resistant Candida albicans in Korea", Annals of Laboratory Medicine, 37(6), pp.556~558 (2017), 대한진단검사의학회